Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the odds of a tumor developing. By Nina Agrawal Scientists have made a discovery ...
Matthew Herper covers medical innovation — both its promise and its perils. CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of ...
Medical artificial intelligence (AI) faces a fundamental challenge: uncertainty quantification. Artificial neural networks ...
Also, senators clashed over Trump’s payout fund. Here’s the latest at the end of Thursday. By Matthew Cullen A group of scientists announced a discovery today that may help prevent some people from ...
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of ...
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that an artificial intelligence (AI)-based ...
Six years after hitting the market as the first targeted treatment for patients with a rare genetic tumor mutation, Eli Lilly’s Retevmo (selpercatinib) is solidifying its legacy with a new study that ...
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. And the first-in-class PD-1xVEGF bispecific didn’t disappoint—at least on its ...
CHICAGO—At the world’s largest oncology conference, Ozempic, a diabetes drug, found its way to the center of the conversation. As thousands of attendees bounced between presentations at the American ...
GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links. The Iron Lung movie based on the video game from YouTube creator ...
Norway’s Crown Princess Mette-Marit has been placed on a waiting list for a transplant due to “life-threatening chronic lung disease,” the country’s royal household has announced. The 52-year-old ...
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based specialist oncology biotech Nuvalent for $10.6 billion. The acquisition could help GSK offset a drop in revenue expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results